Cost-effectiveness of pharmacotherapy for autoimmune hepatitis

Author： Heneghan Michael A   Al-Chalabi Thawab   McFarlane Ian G  

Publisher： Informa Healthcare

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.7, Iss.2, 2006-02, pp. : 145-156

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cost-Effectiveness Analysis of Lamivudine for the Treatment of Chronic Hepatitis B

By Crowley S.J.  

PharmacoEconomics, Vol. 17, Iss. 5, 2000-05 ,pp. : 409-427

Adis International

Access to resources Recommend Favorite

Cost-Effectiveness of Nucleoside Analog Therapy for Hepatitis B in China: A Markov Analysis

By Wu Bin   Li Te   Chen Huafeng   Shen Jinfang  

Value in Health, Vol. 13, Iss. 5, 2010-08 ,pp. : 592-600

Blackwell Publishing

Access to resources Recommend Favorite

Cost–effectiveness analysis in pharmacogenomics

By Payne Katherine   Shabaruddin Fatiha H  

Pharmacogenomics, Vol. 11, Iss. 5, 2010-05 ,pp. : 643-646

Future Medicine

Access to resources Recommend Favorite

Cost-Effectiveness Analyses of Hepatitis A Vaccine: A Systematic Review to Explore the Effect of Methodological Quality on the Economic Attractiveness of Vaccination Strategies

By Anonychuk Andrea M.   Tricco Andrea C.   Bauch Chris T.   Pham Ba'   Gilca Vladimir   Duval Bernard   John-Baptiste Ava   Woo Gloria   Krahn Murray  

PharmacoEconomics, Vol. 26, Iss. 1, 2008-01 ,pp. : 17-32

Adis International

Access to resources Recommend Favorite

A Cost-Effectiveness Analysis of Currently Approved Treatments for HBeAg-Positive Chronic Hepatitis B

By Spackman D. Eldon   Veenstra David L.  

PharmacoEconomics, Vol. 26, Iss. 11, 2008-01 ,pp. : 937-949

Adis International

Access to resources Recommend Favorite